Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
SEC Accession No. 0001193125-25-165139
Filing Date
2025-07-25
Accepted
2025-07-25 11:46:13
Documents
1
Effectiveness Date
2025-07-25

Document Format Files

Seq Description Document Type Size
1 POSASR d26910dposasr.htm POSASR 19575
  Complete submission text file 0001193125-25-165139.txt   20635
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

EIN.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: POSASR | Act: 33 | File No.: 333-267578 | Film No.: 251150240
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)